CapsoVision Inc. Common Stock (CV)

FairStock Score: 22/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is asking $6.78 as of 2026-10-13 for a 99-employee capsule endoscopy outfit with a $339.3M market cap. The product is clever, but the numbers are those of a pre-profitable medtech venture, not a proven compounding machine. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $3.6M, net income was -$7.5M, and diluted EPS was -$0.15. For FY2025, the year ended 2025-12-31, revenue was $13.6M, net income was -$25.3M, and diluted EPS was -$1.03; in FY2024 revenue was $11.8M and net loss was $19.9M. So sales are growing modestly, but losses are widening. FairStock's calculations show negative P/E -6.11 and P/B 26.08 at close, ROE -335.06%, ROCE -132.47%, FCF -$27.9M, FCF yield -8.2%. A Piotroski F-score of 2/9 and FairStock score 22/100 suggest fragile financials. The balance sheet has low D/E 0.05, but cash burn is the real issue. There is no clear moat yet: a tiny revenue base and continuing losses. The Altman Z-score 24.48 is high, but it likely reflects market cap or capital structure rather than durable profits. FairStock's Lynch category is none because only two years of filed results exist; I need more history. At this price, I see speculation on adoption, not a Graham margin of safety.

In plain English: CapsoVision makes swallowable camera devices that take pictures inside the digestive tract. The business is very small and losing money: in its latest reported quarter it had $3.6 million of sales and a $7.5 million loss. The share price looks expensive compared with those weak numbers, and the company is using cash.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer